Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Company Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total value of $1,295,040.00. Following the completion of the sale, the director directly owned 339,875 shares of the company’s stock, valued at $73,358,620. The trade was a 1.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Trading Up 2.1%

NASDAQ:JAZZ traded up $4.92 during trading hours on Wednesday, hitting $234.66. The company had a trading volume of 899,031 shares, compared to its average volume of 934,704. The company has a market capitalization of $15.23 billion, a PE ratio of 79.82, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The stock has a 50-day moving average price of $230.67 and a 200 day moving average price of $216.80. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.04) by $0.16. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.55%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the firm earned $8.13 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 10.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at about $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals during the 2nd quarter valued at about $47,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Jazz Pharmaceuticals during the 2nd quarter valued at about $61,000. Finally, Elevation Wealth Partners LLC boosted its stake in Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 158 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue was about $1.24 billion, up 10.4% year over year and ahead of expectations; the adjusted loss per share was also narrower than consensus. The company raised its 2026 revenue forecast to approximately $4.78 billion–$4.85 billion, above analyst estimates. JAZZ Q3 Earnings & Sales Beat Estimates, Raises ’26 Sales View
• Positive Sentiment: Jazz announced a $500 million share-buyback program, which could return capital to shareholders and support demand for the stock. Jazz Pharmaceuticals announces an equity buyback
• Positive Sentiment: JPMorgan, Morgan Stanley, RBC and Barclays raised their price targets and maintained positive ratings, signaling continued analyst optimism.
• Neutral Sentiment: The company highlighted Ziihera’s launch and its potential peak sales, as well as upcoming brain-cancer clinical data. These offer possible longer-term catalysts, but their impact will depend on commercial progress and trial results. Jazz outlines 2026 revenue guidance and Ziihera sales potential
• Negative Sentiment: Despite beating estimates, Jazz reported an adjusted loss per share, compared with earnings a year earlier. Commentary also flagged slowing growth and an action-related charge as potential concerns for investors. Jazz beats estimates but slowing growth and an action charge pose concerns

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JAZZ. Weiss Ratings cut shares of Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Citigroup initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price objective on the stock. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Finally, Morgan Stanley increased their target price on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $293.45.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.